ELEKTRA

September 10, 2020September 10, 2020

Soticlestat Safely Lowered Seizure Frequency in Children With LGS, Top-line Data Show

uncategorized

Treatment with soticlestat (OV935/TAK-935) safely led to a clinically meaningful reduction in the frequency of hard-to-treat seizures in a group of children with Dravet and Lennox-Gastaut (LGS) syndromes, according to top-line ... Read more

March 19, 2020March 19, 2020

ELEKTRA Trial Testing Soticlestat Completes Early Enrollment of Children With LGS, Dravet

uncategorized

The ELEKTRA trial testing the investigational oral therapy soticlestat (OV935/TAK-935) in children with Lennox-Gastaut syndrome (LGS) and Dravet syndrome has completed patient enrollment, Ovid Therapeutics has announced. “We completed enrollment significantly ahead of ... Read more

October 31, 2019November 14, 2019

Long-term Treatment With Soticlestat Induces Sustained Reduction in Seizure Frequency in Rare Epilepsies, Initial Data Show

Just Published, News

Long-term treatment with the investigational oral therapy soticlestat (OV935/TAK-935) can reduce the median seizure frequency by up to 90% in adults with Lennox-Gastaut syndrome (LGS) and other developmental and epileptic encephalopathies ... Read more